This role is considered Virtual.
Territory Includes: ME, VT, NH, NY, MA, CT, NJ, PA, WV, VA, NC, DE, MD
Overview
Reporting to the Lead, Patient Education Liaison (LPEL), the Patient Education Liaison (PEL) is a critical component of the product brand commercial strategy and works in close coordination with Field Sales, Field Reimbursement, Patient Services, Advocacy, and Marketing teams to support Alnylam’s patient-focused vision of harnessing a revolution in biology for human health.
The Patient Education Liaison is responsible for educating patients, caregivers, families, nurses, medical assistants, office staff, professional nursing organizations, and pertinent community groups on disease state and Alnylam’s RNAi treatments for all Alnylam brands. Using approved materials, the Patient Education Liaison will educate on the disease state, Alnylam treatments, and Alnylam’s services, through phone-based, in-person, and virtual meetings. Central to this role is the ability to work with regional, field-based and internal colleagues to identify barriers to patient access and work to resolve them.
The successful candidate must be passionate about science and deeply motivated by the quest of delivering education to patients and their families with the long-term success of the company in mind. The ideal candidate will be a self-motivated, self-starter with an innovative, entrepreneurial spirit.
Summary Of Key Responsibilities
- Actively collaborates with Field Sales, Patient Services, Medical Affairs, Marketing, Advocacy and other critical internal teams to increase disease-state awareness and early diagnosis
- Leads regional effort to provide disease-state education, treatment education and support to patients their families/caregivers, nurses, medical assistants, office staff, nursing organizations, and community groups
- Maintains disease-state and product expertise through continuing medical education and attendance at relevant symposia, conferences and other educational opportunities
- Provides comprehensive updates on activity to regional colleagues, ensuring that the regional team appropriately works as one entity to support patients in early diagnosis and access to treatment
- Offers constructive feedback on existing workplan and proposes innovative service offerings to leadership where opportunities exist
- Accountable for executing on targeted workplan
- Completes required work in CRM system to facilitate tracking of critical launch metrics
- Ensures compliance with all corporate and industry policies per training provided by Alnylam Commercial, Legal, Regulatory and Compliance Officers
Qualifications
- Bachelor of Science in Nursing, Registered Nurse
- Genetic rare disease/ultra-rare disease experience
- 5+ yrs. Pharmaceutical/biotech experience in a similar role
- Experience supporting and providing education to patients, family members, nurses, medical assistants, office staff, nursing organizations, and community groups affected by rare and ultra-rare genetic diseases (required)
- Strong presentation skills
- Exceptional interpersonal skills, professional communications, problem-solving, compassion and the ability to navigate difficult conversations
- Ability to translate scientific/medical information into patient-friendly language
- Ability to work well and lead within with cross-functional groups and in a matrix organization
- Desire to innovate and work in a fast-paced, energetic environment
- Self-starter who is highly passionate about rare/ultra-rare disease and Alnylam’s core values:
- Commitment to People, Innovation, Discovery, Sense of Urgency, Open Culture, and Passion for Excellence.
- Ability to travel up to 75%
About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.
Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.
